tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

KRTX

Karuna Therapeutics Undergoes Extensive Corporate Transformation
Company AnnouncementsKaruna Therapeutics Undergoes Extensive Corporate Transformation
6M ago
8K
KRTX
Bristol Myers completes acquisition of Karuna Therapeutics
PremiumThe Fly
Bristol Myers completes acquisition of Karuna Therapeutics
6M ago
BMY
KRTX
Karuna Therapeutics reports Q4 EPS ($3.01), consensus ($2.65)
PremiumThe Fly
Karuna Therapeutics reports Q4 EPS ($3.01), consensus ($2.65)
7M ago
BMY
KRTX
Neurocrine price target raised to $106 from $100 at Piper Sandler
PremiumThe Fly
Neurocrine price target raised to $106 from $100 at Piper Sandler
7M ago
CERE
KRTX
Karuna Therapeutics downgraded to Neutral from Buy at Mizuho
PremiumThe Fly
Karuna Therapeutics downgraded to Neutral from Buy at Mizuho
8M ago
BMY
KRTX
The biopharmaceuticals stocks to own in 2024, according to BofA
PremiumThe FlyThe biopharmaceuticals stocks to own in 2024, according to BofA
9M ago
BMY
JNJ
Bristol Myers downgraded to Neutral at BofA as more clarity on execution awaited
Premium
The Fly
Bristol Myers downgraded to Neutral at BofA as more clarity on execution awaited
9M ago
BMY
KRTX
Karuna Therapeutics price target raised to $330 from $197 at UBS
Premium
The Fly
Karuna Therapeutics price target raised to $330 from $197 at UBS
9M ago
KRTX
Karuna Therapeutics downgraded to Neutral from Overweight at JPMorgan
PremiumThe Fly
Karuna Therapeutics downgraded to Neutral from Overweight at JPMorgan
9M ago
BMY
KRTX
RayzeBio deal another ‘incremental positive’ for Bristol, says Morgan Stanley
PremiumThe Fly
RayzeBio deal another ‘incremental positive’ for Bristol, says Morgan Stanley
9M ago
BMY
KRTX
Karuna downgraded, Arm target raised: Wall Street’s top analyst calls
PremiumThe Fly
Karuna downgraded, Arm target raised: Wall Street’s top analyst calls
9M ago
ARM
BMY
M & A News: Bristol-Myers Squibb (NYSE:BMY) to Buy RayzeBio for $4.1B
PremiumMarket News
M & A News: Bristol-Myers Squibb (NYSE:BMY) to Buy RayzeBio for $4.1B
9M ago
AZN
BMY
Karuna deal favorable for Axsome Therapeutics, says H.C. Wainwright
PremiumThe FlyKaruna deal favorable for Axsome Therapeutics, says H.C. Wainwright
9M ago
BMY
AXSM
Reviva may be most undervalued in neurology, says H.C. Wainwright
Premium
The Fly
Reviva may be most undervalued in neurology, says H.C. Wainwright
9M ago
CERE
KRTX
Karuna Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
Premium
The Fly
Karuna Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
9M ago
BMY
AXSM
Karuna Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
PremiumThe Fly
Karuna Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
9M ago
KRTX
Karuna Therapeutics downgraded to Market Perform from Outperform at Leerink
PremiumThe Fly
Karuna Therapeutics downgraded to Market Perform from Outperform at Leerink
9M ago
KRTX
Karuna Therapeutics downgraded to Hold from Buy at Deutsche Bank
PremiumThe Fly
Karuna Therapeutics downgraded to Hold from Buy at Deutsche Bank
9M ago
KRTX
Karuna Therapeutics downgraded to Neutral from Overweight at Piper Sandler
PremiumThe Fly
Karuna Therapeutics downgraded to Neutral from Overweight at Piper Sandler
9M ago
KRTX
Karuna Therapeutics downgraded to Hold from Buy at Maxim
PremiumThe FlyKaruna Therapeutics downgraded to Hold from Buy at Maxim
9M ago
KRTX
Karuna Therapeutics downgraded to Market Perform from Outperform at William Blair
Premium
The Fly
Karuna Therapeutics downgraded to Market Perform from Outperform at William Blair
9M ago
KRTX
Karuna Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
Premium
The Fly
Karuna Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
9M ago
KRTX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >